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Striatal Monoamine Terminals in Lewy Body
Dementia and Alzheimer’s Disease
Sid Gilman, MD, FRCP,1 Robert A. Koeppe, PhD,2 Roderick Little, PhD,3 Hyonggin An, MS,3
Larry Junck, MD,1 Bruno Giordani, PhD,4 Carol Persad, PhD,4 Mary Heumann, BA,1 and Kris Wernette, RN1
We used positron emission tomography (PET) with ()-[11C]dihydrotetrabenazine ([]-[11C]DTBZ) to examine striatal
monoaminergic presynaptic terminal density in 20 patients with dementia with Lewy bodies (DLB), 25 with Alzheimer’s
disease (AD), and 19 normal elderly controls. Six DLB patients developed parkinsonism at least 1 year before dementia
(DLB/PD) and 14 developed dementia before parkinsonism or at about the same time (DLB/AD). Striatal mean binding
potential was decreased by 62 to 77% in the DLB/PD group and 45 to 67% in the DLB/AD compared to AD and
control. Binding was lower in the DLB/PD group than the DLB/AD, but the differences reached only marginal signif-
icance in the caudate nucleus. No differences were found between AD and control groups though a few AD patients had
binding values below the range of the controls. Subsequent neuropathological examination in one AD patient revealed
both AD and DLB changes despite the absence of clinical parkinsonism. Both DLB groups had an anterior to posterior
binding deficit gradient relative to controls, largest in posterior putamen, smaller in anterior putamen, smallest in
caudate nucleus. The DLB/AD group showed significant binding asymmetry only in posterior putamen. We conclude
that PET with ()-[11C]DTBZ differentiates DLB from AD, and decreased binding in AD may indicate subclinical DLB
pathology in addition to AD pathology.
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Dementia with Lewy bodies (DLBs) may be the second
most frequent cause of dementia in the elderly, ac-
counting for 15 to 25% of cases.1 Alzheimer’s disease
(AD) is the most frequent cause and is responsible for
50 to 60% of dementia cases in the elderly. The neu-
ropathological features of DLB include widespread
neuronal degeneration with deposition of Lewy bodies
and Lewy neurites, which contain -synuclein as a ma-
jor filamentous component.2 Substantial neuronal loss
occurs in the substantia nigra and nigrostriatal projec-
tions are decreased. Many cases of DLB show concom-
itant neuropathological changes of AD.1,3 Despite this
overlap, DLB appears to be a distinctive clinicopatho-
logical entity characterized as an -synucleinopathy
along with idiopathic Parkinson’s disease (PD) and
multiple system atrophy.1,4 Lewy bodies contain other
abnormal proteins in addition to -synuclein, notably
parkin.5
The central features of DLB include parkinsonism
with a progressive dementia, and the latter includes
deficits in memory, attention, language, psychomotor
performance, executive functioning, and visuospatial
and visuoconstructive abilities.6 Perceptual and affec-
tive disturbances appear more frequently in DLB than
AD and consist of recurrent visual hallucinations,7,8
delusions,8 depression,7 and agitation.9 Sensitivity to
neuroleptic drugs is prominent.10 Both bradykinesia
and rigidity occur frequently,8 but resting tremor is
rare.8,10 The parkinsonian features in DLB are more
symmetrical than in PD.10 Consensus criteria have
been developed for the clinical diagnosis of DLB,11 but
several prospective and retrospective studies of these
criteria generally have shown limited accuracy. With
neuropathological findings as the gold standard,12–17
these studies have shown the sensitivity of the criteria
to range from 31%17 to 83%16 and the specificity
from 64%15 to 100%.17
Because disease-modifying treatments soon may be-
come available for neurodegenerative dementias, early
diagnosis becomes increasingly important. To this end,
we initiated a positron emission tomography (PET) study
in DLB and AD using ()-[11C]dihydrotetrabenazine
([]-[11C]DTBZ) to examine nigrostriatal projections.
()-[11C]DTBZ binds to the monoaminergic vesicular
transporter type 2 and is useful for evaluating nigro-
striatal projections. The study was designed to detect
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differences in biochemistry, relate the differences to
clinical presentation, and determine whether this li-
gand would be helpful in differentiating cases, particu-
larly in the early stages. We report here the results of
studies with PET and ()-[11C]DTBZ in patients
meeting consensus for DLB,11 patients meeting Na-
tional Institute of Neurological Communicative Disor-
ders and Stroke Alzheimer’s Disease and Related Dis-
orders Association (NINDS-ADRDA) criteria for
AD,18 and a group of elderly normal control subjects.
We selected patients with advanced disorders with the
intention of examining patients in the early stages of
these disorders in a later study.
Subjects and Methods
Subject Selection
The institutional review board of the University of Michigan
approved the investigation. We obtained informed consent
from all participants or their caregivers. We studied 64 sub-
jects, including 25 with AD aged 69.3  9.1 years (mean 
standard deviation; range, 52–85 years, 7 men and 18 wom-
en); 20 with DLB aged 72.8  7.2 years (range, 54–81
years; 15 men and 5 women); and 19 normal elderly controls
aged 69.1  7.6 years (range, 55–86 years; 10 men and 9
women). We used NINCDS-ADRDA criteria for the diag-
nosis of AD18 and consensus criteria11 for the diagnosis of
probable DLB. We divided the DLB cases into two groups,
six who developed parkinsonian features at least 1 year before
dementia appeared (DLB/PD) and 14 who developed de-
mentia before parkinsonism or at about the same time
(DLB/AD).
Subject Evaluations
All subjects were evaluated with general physical and neuro-
logical examinations, neuropsychological evaluations, mag-
netic resonance (MR) scans, PET scans, and appropriate lab-
oratory studies to ensure the accuracy of the clinical
diagnosis. None of the subjects had a history of disturbances
in consciousness, serious head injury, stroke, or abuse of al-
cohol or drugs. All subjects had a modified Hachinski score
of less than 419 and no focal abnormality in computed to-
mography or MR scan except for “bright spots” or mild gen-
eralized atrophy. All subjects had adequate hearing and visual
acuity to complete the studies, including neuropsychological
evaluations. In the patient groups, there were no systemic
diseases or other brain diseases that could account for their
neurological deficits. We evaluated all medications that the
patients were taking and ensured that cognitive impairment
persisted after withdrawal of medications that might impair
cognition. If depressive features were found, we made certain
that the dementia did not reverse with antidepressants. Thir-
teen DLB patients were taking carbidopa/L-dopa, but this
medication has no effect on binding of ()-[11C]DTBZ.
The laboratory studies included a complete blood count, sed-
imentation rate, chemical profile, urinalysis, serological test
for syphilis, thyroid studies, and serum levels of vitamin B12
and folic acid. These studies were normal or judged to be
clinically insignificant. Although ()-[11C]DTBZ binding is
not known to be altered by medications, medications that
might influence dopaminergic presynaptic neurons were dis-
continued 4 weeks before the PET study.
Neuropsychological Testing
We assessed general mental status and orientation with the
Mini-Mental State Examination (MMSE),20 attention with
the Digit Span test,21 language with the Multilingual Apha-
sia Examination Visual Naming Test,22 visual-spatial ability
with the Visual Form Discrimination Test,23 memory with
the Hopkins Verbal Learning Test–Revised,24 and family rat-
ings of general motor ability with the motor subscale of the
Inventory of Psychic and Somatic Complaints–Elderly.25
Positron Emission Tomography Imaging
We injected 18  1.8mCi of ()-[11C]DTBZ to measure
the density of striatal monoaminergic terminals.26,27 This
stereospecific ligand has a high affinity (KD  1 nM) for the
vesicular monoamine transporter type 2 (VMAT2) site. The
radiotracer was administered as a partial bolus (55% of the
injected dose) followed by continuous infusion (the remain-
ing 45%) over the duration of the PET study. In the course
of this investigation, we replaced our PET scanner. Conse-
quently, we studied 25 subjects with a Siemens/CTI ECAT
Exact-47 scanner (10 DLB patients, 9 AD patients, and 6
normal controls) and 39 subjects with a Siemens/CTI ECAT
Exact HR scanner (10 DLB patients, 16 AD patients, and
13 normal controls). All scans were performed in three-
dimensional mode with the interplane septa retracted. Mea-
sured attenuation correction was performed from a 6 to 10-
minute-duration two-dimensional transmission scan followed
by segmentation and reprojection. Scatter correction also was
performed on all scans. After Fourier rebinning (FORE) of
the three-dimensional data into two-dimensional data sets,
scans were reconstructed with smoothing parameters selected
that provided images for both scanners with in-plane and
axial resolution of approximately 8.5mm full-width at half-
maximum. Statistical checks showed that any residual scan-
ner effects were negligible and had no substantive impact on
any of the results or conclusions.
Data Analysis
The continuous infusion protocol for [11C]DTBZ admin-
istration allows an equilibrium analysis to be performed.27
An index of the density of striatal presynaptic monoamin-
ergic terminals was estimated as the distribution volume ra-
tio (DVR) relative to occipital cortex, or equivalently as the
normalized specific binding density called the binding po-
tential (BP), which equals DVR-1. The occipital cortex
served as a reference region containing negligible specific
binding, thus reflecting the distribution volume of free plus
nonspecifically bound [11C]DTBZ. DVR was measured in
the caudate nucleus and in the anterior and posterior pu-
tamen using three-dimensional rectangular volumes of in-
terest (VOIs) of 4.5  9  4.5mm. VOIs were centered on
the areas of greatest DVR in the caudate nucleus, then
moved successively 11 and 20mm posteriorly, and recen-
tered on the area of greatest DVR in the anterior and pos-
terior putamen, respectively. Striatal binding values were
calculated as the simple average of values in both hemi-
spheres for each of the three regions. Percentage of asym-
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metry of binding was measured in each of the three striatal
regions as the absolute difference in regional BP values in
the right and left hemispheres divided by the mean of the
two sides. Differences between patient and control mean
BP values for striatal ()-[11C]DTBZ binding were exam-
ined by analysis of variance, and t tests were used for pair-
wise comparisons. To adjust for age and sex, we included
these variables as covariates in regression models of the stri-
atal binding values on subject group. For regressions of
asymmetry of binding, cases were weighted by their striatal
binding values to allow for nonconstant variance.
Results
Subject Group Comparisons
The four groups did not differ in mean age (p 
0.41), but the AD group contained a higher propor-
tion of women than the other groups (Table 1). Symp-
tom duration was longer in the DLB/PD group than
the other two patient groups. There was no difference
between patient groups in either mean MMSE scores
(see Table 1) or in other tests that sampled major cat-
egories of cognitive functions, including attention, lan-
guage, visual-spatial ability, and memory (p  0.35).
The only difference found was in motor ability (see
Table 1).
Striatal ()-[11C]Dihydrotetrabenazine Binding
The Figure contains the binding potential values for
striatal ()-[11C]DTBZ binding of normal control
subjects, AD patients, and DLB/AD and DLB/PD pa-
tients for the caudate nucleus, anterior putamen, and
posterior putamen. The illustration shows a broader
range of values in all three structures for the AD group
in comparison with the normal control group, but no
other difference. In contrast, values for both DLB
groups are appreciably lower than the other two
groups, with the DLB/PD generally lower than the
DLB/AD group. Only a few DLB cases show overlap
with either of the other groups, and no overlap occurs
between the DLB and normal control groups in either
anterior or posterior putamen.
Table 2 contains the age- and sex-adjusted mean and
raw standard deviation of BP by striatal structure. In the
caudate nucleus, anterior putamen, and posterior puta-
men, mean binding potential is decreased by 62 to 77%
in the DLB/PD group and by 45 to 67% in the
DLB/AD group compared with AD and control groups
(p  0.001 in all cases). There is a marginal difference
between DLB/AD and DLB/PD groups in the caudate
nucleus only and no difference between control and AD
groups. Table 2 shows a gradient of BP decline in both
DLB groups relative to the control group across individ-
ual components of the striatum, with the greatest decline
in the posterior putamen (70%), a smaller decline in
the anterior putamen (64%), and the smallest decline,
though still substantial, in the caudate nucleus (50%).
These declines in the DLB groups relative to the control
and AD groups are significant in all three striatal struc-
tures (p  0.0001).
Table 3 shows the age- and sex-adjusted weighted
mean and raw standard deviation of relative asymmetry
of BP for normal control, AD, and DLB groups by
striatal structure. There are no significant differences
between groups for the caudate nucleus and anterior
putamen, but for the posterior putamen the DLB/AD
group has a higher relative asymmetry than the control
and AD groups (p  0.03).
Autopsy Verification of Diagnosis
Three patients died between 18 and 40 months after
study, including one in the DLB/AD group and two in
Table 1. Subject Characteristics
Characteristic NC (n  19) AD (n  25) DLB/AD (N  14) DLB/PD (n  6)
Sex (M:F) 10:9 7:18a 11:3 4:2
Age (yr) (range) 69.1  7.6 (55–86) 69.3  9.1 (52–85) 73.4  5.1 (65–80) 71.5  11.2 (54–81)
MMSE (range) 29  1 (26–30) 15  7 (2–27) 17  6 (8–29) 18  9 (6–26)
Symptom duration (yr) Not applicable 5  3 (1–13) 4  2 (2–7) 8  3b (5–13)
Motor functioning Not applicable 3.3  3.7 (0–12) 6.5  3.0c,d (2–10) 12.7  3.1c,e (10–16)
Data include mean  standard deviation and range.
1Motor function established from family ratings of general motor ability with the motor subscale of the Inventory of Psychic and Somatic
Complaints–Elderly.
aLarger proportion of women than men in this group than the other groups (p  0.005).
bLonger symptom duration in DLB/PD than in the other groups (p  0.01).
cGreater impairment in DLB/AD than in AD (p  0.02).
dGreater impairment in DLB/PD than in DLB/AD (p  0.009)
eGreater impairment in DLB/PD than in AD (p  0.0001).
NC  normal control; AD  Alzheimer’s disease; DLB/AD  patients with a diagnosis of dementia with Lewy bodies who developed
parkinsonian symptoms simultaneously with or after the onset of dementia; DLB/PD  patients with a diagnosis of dementia with Lewy bodies
who developed parkinsonian symptoms at least 1 year before dementia; MMSE  Mini-Mental State Examination.
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the AD group. At neuropathological examination, the
DLB/AD patient had changes typical of DLB without
evidence of AD. In this patient, the BP value was the
second lowest of the DLB group in both the caudate
nucleus and anterior putamen, and the lowest of the
group in the posterior putamen (see Fig). One of the
AD patients had neuropathological changes character-
istic of AD without evidence of DLB, and the BP val-
ues in this case were approximately in the middle of
the AD group for all three striatal structures. The sec-
ond AD patient had neuropathological findings typical
of both AD and DLB, and the BP value was nearly
normal in the caudate nucleus (11th lowest of 25) but
was fourth lowest in the anterior putamen, and second
lowest in the posterior putamen (see Fig). This patient
showed no clinical evidence of parkinsonism at the
time of study and died 18 months after participating.
The patient was examined twice between the time of
study and the time of death, and at the second exam-
ination 3 months before death the parkinsonian fea-
tures of mild bradykinesia of face and body with mild
rigidity of the limbs were found for the first time.
Discussion
This investigation disclosed significantly decreased stri-
atal binding of ()-[11C]DTBZ in DLB/AD and
DLB/PD patients as compared with both AD and nor-
mal control subjects and no difference between the lat-
ter two groups. Binding was significantly decreased in
all three striatal structures of both DLB groups, with
the largest decreases in the posterior putamen and pro-
gressively smaller decreases in the anterior putamen
and caudate nucleus, respectively. Binding was margin-
ally lower in the DLB/PD than in the DLB/AD group,
with a significant difference only in the caudate nu-
cleus. Significantly higher binding asymmetry between
the two hemispheres was found for the DLB/AD group
as compared with the other groups in the posterior pu-
tamen, but no group differences were found in the
caudate nucleus or anterior putamen. The mean asym-
metry values between the DLB/AD and DLB/PD
groups were similar and the different significance val-
ues most likely reflect lesser power in the DLB/PD
group because of fewer cases. Greater binding asymme-
try has been reported in Parkinson’s disease than in the
present DLB cases.28,29 Parkinson’s disease characteris-
Fig. Binding potential values for striatal ()-[11C]DTBZ
binding of normal control (NC) subjects, patients with Alzhei-
mer’s disease (AD), patients with a diagnosis of dementia with
Lewy bodies who developed parkinsonian symptoms at least 1
year before dementia (DLB/PD), and patients with a diagno-
sis of dementia with Lewy bodies who developed parkinsonian
symptoms simultaneously with or after the onset of dementia
(DLB/AD). Binding potential values are shown for the cau-
date nucleus, anterior putamen, and posterior putamen. Open
symbols indicate the three patients who later came to postmor-
tem examination. The lower of the two open symbols in the
AD columns indicates the patient who had neuropathological
changes of both AD and DLB.
Table 2. Mean and Standard Deviation of the Binding Potential for Each Striatal Structure after Adjustment for the
Covariates of Age and Sex
NC AD DLB/AD DLB/PD
Caudate nucleus 1.73  0.23a 1.75  0.35a 0.95  0.29b,c 0.66  0.27b,c
Anterior putamen 2.00  0.27a 2.07  0.41a 0.80  0.25b,d 0.54  0.19b,d
Posterior putamen 1.94  0.25a 1.94  0.42a 0.65  0.23b,d 0.45  0.18b,d
aNo significant differences in group means (p  0.48).
bMeans for DLB/PD and DLB/AD are lower than means for NC and AD groups (p  0.001).
cMean for DLB/PD is marginally lower than mean for DLB/AD (p  0.05).
dMeans for DLB/PD and DLB/AD are not different (p  0.1).
NC  normal control; AD  Alzheimer’s disease; DLB/AD  patients with a diagnosis of dementia with Lewy bodies who developed
parkinsonian symptoms simultaneously with or after the onset of dementia; DLB/PD  patients with a diagnosis of dementia with Lewy bodies
who developed parkinsonian symptoms at least 1 year before dementia.
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tically shows marked asymmetry in both presynaptic
terminals28 and dopaminergic D2 receptors,29 with the
asymmetry correlated to the clinical findings.
We selected cases for study with established diag-
noses by currently accepted clinical criteria. The pur-
pose was to determine whether these studies would
clearly separate the groups, and, if so, we planned to
carry the study into patients with early dementia. The
cases selected had equivalent levels of dementia and
were well matched in age and duration of disease. The
major difference between patient groups was the higher
proportion of women in the AD than in the DLB
group, reflecting in part the relative prevalence of these
disorders in the two sexes. Other factors may have con-
tributed to these differences, but we avoided systematic
selection bias by accepting all patients who met diag-
nostic criteria and agreed to participate. All DLB pa-
tients fulfilled criteria for probable DLB according to
consensus criteria,11 and all had clear parkinsonian fea-
tures.
The finding of decreased striatal monoaminergic ter-
minals in DLB was not surprising, because these pa-
tients all had identifiable features of parkinsonism, in-
cluding bradykinesia, masked face, limb rigidity, and
parkinsonian gait. Moreover, as anticipated, we found
lower binding levels in the DLB patients whose disor-
ders began with parkinsonian features initially in com-
parison with those whose disorders began with demen-
tia. One surprising finding was that a few AD patients
had binding values below the lower limit of the normal
control group, notably in the posterior putamen. We
obtained a postmortem examination in one of these
cases and found changes typical of both DLB and AD.
This patient exhibited no parkinsonian features at the
time of study, and mild bradykinesia and rigidity were
detected 15 months after the study, 3 months before
death. This indicates that the decline in monoaminer-
gic presynaptic terminals occurs well in advance of
clinical evidence of parkinsonism and lends some cre-
dence to the possibility that in mild cognitive impair-
ment or early dementia we may be able to differentiate
AD from DLB using PET with ()-[11C]DTBZ. Neu-
ropathology findings on a second patient from the AD
group showed no changes typical of DLB and this sub-
ject had normal DTBZ binding.
Several published functional brain imaging studies of
AD, PD, and DLB cases are relevant to the current
investigation. The approaches used have included PET
studies of local cerebral metabolic rates for glucose
(lCMRglc),30 single-photon emission computed to-
mography (SPECT) investigations of local cerebral
blood flow,31 and both PET32–35 and SPECT36–39
studies of nigrostriatal projections using ligands that la-
bel dopaminergic presynaptic or postsynaptic sites.
Three studies examined striatal dopaminergic presynap-
tic terminals in various groups of cases that included
PD, DLB, AD and normal age-appropriate controls us-
ing PET with the striatal dopaminergic presynaptic li-
gand [18F]fluorodopa32–34 and one with the dopamine
presynaptic reuptake ligand [11C]	-CFT.35 One study
using [18F]fluorodopa in a small group of subjects re-
ported results similar to those in the present investiga-
tion, that is, decreased uptake in the caudate nucleus
and putamen in DLB as compared with AD and nor-
mal controls, and no difference between AD and con-
trol groups.32
The current investigation augments previous studies
by showing a marked decrease of striatal binding in
DLB, below the range of the normal control group and
below the range of most AD patients. Moreover, our
findings suggest that AD patients who have striatal
binding below the range of the normal controls and in
the upper range of the DLB cases may be developing
the neuropathological changes of DLB in advance of
clinical evidence of parkinsonism. This study shows in
DLB patients a modest but significant asymmetry of
binding in the posterior putamen but not in the cau-
date nucleus or anterior putamen. Additional studies
will be needed to compare these findings with a group
of PD patients with normal cognition to determine
whether relative asymmetry of binding might be a use-
ful means of determining whether a disorder that ap-
Table 3. Mean and Standard Deviation of the Percentage of Asymmetry of the Binding Potential of Striatal Structures after
Adjustment for the Covariates of Age and Sex by Weighted ANCOVA
NC (%) AD (%) DLB/AD (%) DLB/PD (%)
Caudate nucleus 4.4  3.2a 6.9  6.0a 7.0  5.8a 3.6  6.1a
Anterior putamen 5.2  2.5a 4.4  4.8a 7.9  8.9a 6.7  3.4a
Posterior putamen 6.7  3.7a,b 4.8  8.3a,b 14.5  18.1b,c 16.5  12.6c
aNo significant group difference in group means (p  0.1).
bMean for DLB/AD is higher than means for NC and AD (p  0.03).
cMeans for DLB/PD and DLB/AD are not different (p  0.8).
NC  normal control; AD  Alzheimer’s disease; DLB/AD  patients with a diagnosis of dementia with Lewy bodies who developed
parkinsonian symptoms simultaneously with or after the onset of dementia; DLB/PD  patients with a diagnosis of dementia with Lewy bodies
who developed parkinsonian symptoms at least 1 year before dementia.
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pears to be PD may later evolve into DLB. Finally, the
findings presented here suggest that PET with ()-
[11C]DTBZ may be used in patients with mild cogni-
tive impairment or early dementia to differentiate those
who will evolve to develop AD from those who will
develop AD coupled with DLB. In this context, note
that many patients have the combined pathology of
AD and DLB.40,41
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